Sumitomo Pharma Co., Ltd. (FRA:DPM)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.01B +8.2% |
| Revenue (ttm) | 2.56B +14.1% |
| Net Income | 606.65M +496.0% |
| EPS | 1.49 +481.9% |
| Shares Out | n/a |
| PE Ratio | 6.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 8.72 |
| Previous Close | 9.02 |
| Day's Range | 8.72 - 8.72 |
| 52-Week Range | 6.65 - 18.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agre... [Read more]
Financial Performance
In fiscal year 2026, Sumitomo Pharma's revenue was 453.29 billion, an increase of 13.66% compared to the previous year's 398.83 billion. Earnings were 106.87 billion, an increase of 352.17%.
Financial numbers in JPY Financial StatementsNews
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa...
Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has been Certified™ by Great Place To Work® for July 2026-2027. The prestigious award is based entirel...
Sumitomo Pharma Earnings Call Transcript: Q1 2027
Q1 FY 2026 saw strong revenue growth driven by U.S. sales of ORGOVYX and GEMTESA, offsetting declines from divestitures and expired agreements. Net profit rose on FX gains, while R&D and SG&A costs increased. Management remains cautious on full-year guidance, with dividend resumption under review.
Sumitomo Pharma Quarterly report: Q1 2027
Sumitomo Pharma has published its Q1 2027 quarterly earnings report on July 31, 2026.
Sumitomo Pharma Slides: Q1 2027
Sumitomo Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to enzomenib (DSP-5336) f...
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new clinical and translational research at the European Hematology Association (EHA) 2026 ...
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomeni...
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced clinical data from its ongoing first-in-human Phase 1/2 trial of SMP-3124LP (NCT06526819). SMP-3124LP is a str...
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (...
Sumitomo Pharma Earnings Call Transcript: Q4 2026
FY 2025 saw double-digit revenue and profit growth, driven by U.S. sales of ORGOVYX and GEMTESA, while Japan faced headwinds from loss of exclusivity and price revisions. FY 2026 guidance projects further revenue gains, increased R&D, and a focus on new product launches and financial stability.
Sumitomo Pharma Quarterly report: Q4 2026
Sumitomo Pharma has published its Q4 2026 quarterly earnings report on May 13, 2026.
Sumitomo Pharma Slides: Q4 2026
Sumitomo Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Sumitomo Pharma Slides: Investor presentation
Sumitomo Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.
Sumitomo Pharma Earnings Call Transcript: Q3 2026
Q3 FY2025 saw strong revenue and profit growth, driven by North American product sales and cost controls. Full-year guidance is unchanged due to expected Q4 seasonality, while oncology R&D and partnering timelines have shifted to maximize asset value.
Sumitomo Pharma Quarterly report: Q3 2026
Sumitomo Pharma has published its Q3 2026 quarterly earnings report on January 30, 2026.
Sumitomo Pharma Slides: Q3 2026
Sumitomo Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Sumitomo Pharma Earnings Call Transcript: Q2 2026
Q2 FY2025 saw revenue and profit surge above forecasts, driven by strong North America sales, a JPY 49 billion gain from the China-Asia business transfer, and disciplined cost control. Full-year guidance was raised, with Orgovyx expected to surpass $1 billion in sales.
Sumitomo Pharma Quarterly report: Q2 2026
Sumitomo Pharma has published its Q2 2026 quarterly earnings report on October 31, 2025.
Sumitomo Pharma Slides: Q2 2026
Sumitomo Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 31, 2025.
Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Sumitomo Pharma (DNPUF) to Equal Weight from Underweight with a price target of 1,350 yen, up from 550 yen. Orgovyx sales are “on a roll” with U.S.
Sumitomo Pharma Earnings Call Transcript: Q1 2026
Q1 FY2025 saw strong revenue and profit growth, led by North America, with ORGOVYX and GEMTESA outperforming plans. Full-year guidance is unchanged due to uncertainties, but significant one-time gains are expected in H1. R&D and governance initiatives continue to advance.
Sumitomo Pharma Quarterly report: Q1 2026
Sumitomo Pharma has published its Q1 2026 quarterly earnings report on July 31, 2025.
Sumitomo Pharma Slides: Q1 2026
Sumitomo Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 31, 2025.